Physician profile
Adrian Dirk
NPI 1841553153
$4,745.19
in general payments reported to CMS, 2019-2025
34 companies · $932 in 2025
The $932 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $85.88 · 2021: $414 · 2022: $518 · 2023: $803 · 2024: $1,231 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $893.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $835.83 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $633.64 | 2019-2025 | |
| Astellas Pharma US INC | $254.50 | 2019-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $253.58 | 2019-2025 | Qelbree, Qelbree |
| Lilly USA, LLC | $252.70 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $214.52 | 2019-2023 | |
| Glaxosmithkline, LLC. | $193.67 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $127.61 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $114.51 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $112.22 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Si-Bone, INC. | $75.10 | 2019 | |
| Amgen INC. | $75.09 | 2019-2024 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $63.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.51 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.59 | 2019-2021 | |
| Exact Sciences Corporation | $53.15 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $50.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $50.19 | 2024-2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $49.07 | 2024-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $47.86 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $40.72 | 2023 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.16 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $30.81 | 2020 | |
| Dexcom, INC. | $30.08 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.01 | 2022 | |
| Acadia Pharmaceuticals INC | $23.20 | 2022 | |
| Esperion Therapeutics, INC. | $19.77 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.55 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $14.82 | 2025 | Inspire |
| Tris Pharma INC | $13.91 | 2019 | |
| Amarin Pharma, INC. | $11.67 | 2019 | |
| Circassia INC. | $11.00 | 2019 | |
| Allergan, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Dirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.